As biopharmas pledge scientific transparency, scrutiny intensifies ahead of FDA’s COVID-19 vaccines panel

The pledge by nine biopharma CEOs to adhere to high ethical and scientific standards in the development of COVID-19 vaccines will intensify the focus on an upcoming FDA advisory committee meeting.

Public confidence rests not just on the actions companies take, but even more on the decisions FDA makes. FDA’s Vaccines and Related Biological Products Advisory Committee meeting on Oct. 22 will provide an opportunity for the agency to describe how it will make decisions, and for independent experts to provide perspectives that the public can use to judge FDA’s actions...